HNGE vs OCGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HNGE is the larger of the two ($9.80B market cap): the incumbent the market prices for continued execution (37.32x forward earnings). OCGN is the smaller challenger ($328.35M), priced similarly on forward earnings (-3.82x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

HNGE vs OCGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricHNGEOCGNWhat it tells you
Market cap$9.80B$328.35MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E37.32-3.82Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range96% of range14% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how HNGE and OCGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HNGE and OCGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HNGE and OCGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Hinge Health (HNGE) do?

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

What does Ocugen (OCGN) do?

Ocugen, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on gene and cell therapies for eye diseases. Its core asset is a modifier gene-therapy platform that uses nuclear hormone receptor genes to address disease across many genetic mutations rather than one at a time. The lead program, OCU400, targets broad retinitis pigmentosa in the Phase 3 liMeliGhT trial; OCU410 targets geographic atrophy secondary to dry age-related macular degeneration; and OCU410ST targets Stargardt disease. The company has framed a goal of pursuing three biologics license applications across these programs, with the first, for OCU400, now planned for the second quarter of 2027 after Phase 3 topline data in the first quarter, and also runs earlier-stage work in other modalities.

Full OCGN guide

HNGE vs OCGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.
  • OCGN drivers: Lead program advancing toward a regulatory decision; A platform, not a single shot on goal.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. For OCGN, ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval.

HNGE or OCGN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HNGE if you believe its drivers more; OCGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HNGE and OCGN guides.

HNGE vs OCGN: the full fundamentals

HNGE. Hinge Health's valuation has moved from a story about reaching profitability to one about sustaining fast, profitable growth. At about 33x trailing and forward earnings and 11x sales after a ~123% year-to-date gain, the shares sit just below the ~$112 average analyst target, so the November 2 third-quarter report (consensus ~$0.60 EPS on ~$224.8 million of revenue) will be read for whether growth near 50% can hold.

OCGN. Ocugen is pre-profit and has no product revenue, so traditional earnings metrics do not apply; what matters is cash runway versus burn. Cash of ~$100 million at June 30, 2026 followed the 2026 convertible note offering, which management said would extend the runway into 2028, while trailing operating cash outflow ran ~$61 million and the second-quarter loss widened to ~$24.9 million. Analysts expect a loss of about $0.05 per share for the third quarter, with results expected around November 5, 2026. Figures are approximate and can move materially with new raises or spending changes.

Headline figures (approximate, October 2026): HNGE shows revenue (ttm) ~$720 million; Q2 2026 ~$212.8 million, up ~53% year over year, gross / operating margin ~85% / ~19%, net income (ttm) ~$107 million (Q2 2026 ~$43.1 million), adjusted eps (q2 2026) ~$0.59 vs ~$0.62 estimate; OCGN shows market capitalization ~$273 million at ~$0.80 per share (Oct 16, 2026), shares outstanding ~339 million, revenue (ttm, collaboration/other) ~$4.6 million, net loss (ttm) ~$81.8 million (~$0.26 per share).

The bottom line: HNGE vs OCGN

HNGE and OCGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HNGE and OCGN exposure against your real portfolio. It is not an investment adviser.

Wondering how HNGE or OCGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Hinge Health

Ask Walnut's AI anything about HNGE and see how it fits what you own.

FAQ

What is the difference between HNGE and OCGN?

+

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. Ocugen, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is HNGE or OCGN the better stock?

+

Neither is universally better. HNGE is the larger incumbent; OCGN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, HNGE or OCGN?

+

On forward P/E (as of November 2026), HNGE trades at 37.32x and OCGN at -3.82x, so OCGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both HNGE and OCGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of HNGE vs OCGN?

+

HNGE: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. Employer benefits cycle and economic pressure can slow new logo growth. Member engagement determines outcomes and ROI to customers; engagement scaling must continue. Valuation is now the most visible risk: after a ~100% one-year gain the stock trades around 33x trailing earnings, 11x sales and 24x book value as of October 2026, so a revenue deceleration or another small EPS miss like Q2 2026 (~$0.59 versus ~$0.62 expected) could move the shares sharply. Recent IPO dynamics persist, with continuing insider sales, including a ~$20.6 million sale disclosed in October 2026, adding supply and shaping sentiment. OCGN: Ocugen is a speculative, clinical-stage company with no approved products and no meaningful product revenue, so its programs may fail in trials or fall short of regulatory approval. The company funds itself from a limited cash balance and recurring capital raises, and it has historically issued equity and convertible debt that dilute existing shareholders. It competes with larger, better-funded gene-therapy and ophthalmology developers. A single negative readout or regulatory setback could sharply reduce the stock's value. Two newer risks apply as of October 2026. The shares closed at ~$0.80 on October 16, below Nasdaq's $1.00 minimum bid requirement, and a sustained period under that level can trigger a deficiency notice and, if not cured, a reverse split or delisting. The U.S. BLA timeline has also moved out, from a rolling filing guided for the third quarter of 2026 to a planned submission in the second quarter of 2027, which lengthens the period the company must fund before any U.S. approval decision.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HNGE or OCGN; figures are approximate and dated (as of November 2026). Verify current data before investing.